1. Home
  2. MCBS vs IVVD Comparison

MCBS vs IVVD Comparison

Compare MCBS & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MetroCity Bankshares Inc.

MCBS

MetroCity Bankshares Inc.

N/A

Current Price

$26.54

Market Cap

827.1M

Sector

Finance

ML Signal

N/A

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$2.42

Market Cap

692.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MCBS
IVVD
Founded
2006
2020
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
827.1M
692.7M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MCBS
IVVD
Price
$26.54
$2.42
Analyst Decision
Hold
Strong Buy
Analyst Count
1
5
Target Price
$31.00
$8.75
AVG Volume (30 Days)
45.9K
4.8M
Earning Date
01-20-2026
11-06-2025
Dividend Yield
3.77%
N/A
EPS Growth
11.15
N/A
EPS
2.59
N/A
Revenue
$147,349,000.00
$50,039,000.00
Revenue This Year
$13.89
$103.88
Revenue Next Year
$33.10
$171.40
P/E Ratio
$10.25
N/A
Revenue Growth
8.69
332.71
52 Week Low
$24.24
$0.35
52 Week High
$34.91
$3.07

Technical Indicators

Market Signals
Indicator
MCBS
IVVD
Relative Strength Index (RSI) 40.16 50.81
Support Level $27.01 $2.52
Resistance Level $27.08 $2.85
Average True Range (ATR) 0.56 0.20
MACD -0.24 -0.02
Stochastic Oscillator 4.36 29.52

Price Performance

Historical Comparison
MCBS
IVVD

About MCBS MetroCity Bankshares Inc.

MetroCity Bankshares Inc is a holding company of its subsidiary Metro City Bank. It provides commercial banking services such as consumer and commercial checking accounts, savings accounts, certificates of deposits, commercial and consumer loans, money transfers and a variety of other banking services. The banks generate revenue from interest income. Its customers include small business owners, professionals, consumers, and real estate developers.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: